CDP and technology innovation catalyst CPI today launch A Strategic Technology Roadmap for the UK In Vitro Diagnostics Industry, a major new report for industry leaders, government, and the UK’s health tech companies.
Our Roadmap defines the key technologies and strategies that can place the UK at the forefront of the IVD industry.
Pregnancy screening, cancer treatment, organ transplant – digital PCR testing has the power to enhance clinical decision-making. What’s needed to take it mainstream?
Having developed a highly effective liquid biopsy system to isolate CTCs, Vortex Biosciences needed our technical expertise and manufacturing experience to improve the system’s disposable cartridge for reliable performance and high-volume production.
Senior Consultant Sergio Malorni shares seven principles we apply when conducting technology due diligence, whether for rights acquisition or investment in the company which owns the target technology.
In collaboration with deep tech innovation partner CPI and supported by Innovate UK, Cambridge Design Partnership is constructing a new actionable capability and technology roadmap for the in vitro diagnostics industry.
With urgent and important demand for LFTs, jeopardizing performance, ease-of-use, supply chain availability, and low cost isn’t an option – but sustainability strategies are evolving in response to consumer expectations.
Ice cream and blood are two things you probably don’t want to think about simultaneously, but how a substance flows is a vitally important consideration for many products.
In an intense disaster or battlefield scenario, correctly identifying which victim to treat first can be a matter of life or death, so we created a specialised wearable monitor. The device won the prestigious ‘Best of the Best’ Red Dot award.
The aim was to disrupt the diagnostics market with a lancing system that would significantly improve the patient’s experience. Our development and regulatory teams helped our client launch the first FDA & CE approved device for fully automated, virtually pain-free lancing.
CDP’s partner QuantuMDx has now embarked on £11 million scale-up to mass manufacture of their Q-POC™ device.
The Covid-19 pandemic has presented a time-limited but immense window of opportunity for diagnostics companies. Changes in regulation and increased levels of investment are enabling radical innovations to have real impact, but only if they can be fast-tracked into new products which are cost effective and compelling to users. In…